D
David A. Hume
Researcher at University of Queensland
Publications - 612
Citations - 66127
David A. Hume is an academic researcher from University of Queensland. The author has contributed to research in topics: Macrophage & Macrophage colony-stimulating factor. The author has an hindex of 113, co-authored 573 publications receiving 59932 citations. Previous affiliations of David A. Hume include University of California, San Diego & University of Oxford.
Papers
More filters
Journal ArticleDOI
Resting and injury-induced inflamed periosteum contain multiple macrophage subsets that are located at sites of bone growth and regeneration.
Kylie A. Alexander,Liza-Jane Raggatt,Susan M. Millard,Lena Batoon,Andy Wu,Ming-Kang Chang,David A. Hume,David A. Hume,Allison R. Pettit +8 more
TL;DR: Observations confirm that osteomacs are key components of both osteal tissues, in spite of salient differences between endosteal and periosteal structure and that multiple macrophage subsets are involved in peruosteal bone dynamics.
Journal ArticleDOI
Regulation of the plasminogen activator inhibitor-2 (PAI-2) gene in murine macrophages. Demonstration of a novel pattern of responsiveness to bacterial endotoxin.
TL;DR: PAI‐2 mRNA levels generally varied inversely from those of its target, urokinase‐type plasminogen activator (uPA), and the macrophage growth factor CSF‐1, which induces uPA, inhibited PAI‐ 2 expression in cells treated subsequently with LPS.
Journal ArticleDOI
Effector ExoU from the Type III Secretion System Is an Important Modulator of Gene Expression in Lung Epithelial Cells in Response to Pseudomonas aeruginosa Infection
Brendan J. McMorran,Liam Town,Elaine O. Costelloe,James S. Palmer,Joanne N. Engel,David A. Hume,Brandon J. Wainwright +6 more
TL;DR: A detailed insight is provided into the response of epithelial cells to infection and the significant role played by the type III virulence mechanism in the initial host response is indicated.
Journal ArticleDOI
S100A8 chemotactic protein is abundantly increased, but only a minor contributor to LPS-induced, steroid resistant neutrophilic lung inflammation in vivo
Steven Bozinovski,Maddalena Cross,Ross Vlahos,Jessica E. Jones,Kenneth Hsuu,Philippe A. Tessier,Eric C. Reynolds,David A. Hume,John A. Hamilton,Carolyn L. Geczy,Gary P. Anderson +10 more
TL;DR: S100A8, despite its abundance, resistance to steroids and known chemotactic activity, is unlikely to be an important determinant of LPS-induced neutrophilic lung inflammation in vivo, and the need for extensive in vivo profiling of proteomically identified candidate molecules is demonstrated.
Journal ArticleDOI
Network Analysis Reveals Distinct Clinical Syndromes Underlying Acute Mountain Sickness
David Hall,Ian J. C. MacCormick,Alexander T. Phythian-Adams,Nina Marie Rzechorzek,David Hope-Jones,Sorrel Cosens,Stewart J. Jackson,Matthew G.D. Bates,David Collier,David A. Hume,Tom C. Freeman,A. A. Roger Thompson,J K Baillie +12 more
TL;DR: The results challenge the accepted paradigm that AMS is a single disease process and describe at least two distinct syndromes following acute ascent to high altitude, and have potential utility in other clinical Syndromes.